« Return to News | Awards & Advancement

Chiltern promotes Aize Smink and Linda Christmas

Thursday, November 29, 2012 08:00 AM

Chiltern International, a global CRO, has promoted Aize Smink and Linda Christmas to executive positions, coinciding with Dr. Jim Esinhart’s appointment as CEO.

Aize Smink, previously senior executive vice president of global clinical development, has been named chief operating officer. In this new position he will provide leadership and oversight of Chiltern’s global clinical development and global scientific services divisions. Aize has more than 20 years of development experience in the pharmaceutical, biotech and medical device industries and joined Chiltern in 2006. He is based in Brussels, Belgium.

Linda Christmas, formerly senior executive vice president of global resourcing solutions, will now serve as chief resourcing officer in recognition of her role as the global head of Chiltern’s global resourcing solutions division and leading select corporate services which include human resources, marketing and recruitment. Christmas has more than 25 years of clinical research experience and has been with Chiltern since 1997. She is based in Slough, U.K.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.